Calvary Health Care Bethlehem Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial
2016
NCT02868580
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Calvary Bethlehem | Calvary Health Care Bethlehem

Active Ingredients

Drugs in Phase 2 Trials (5)

abacavir (ziagen) (1 trial)

acetylcysteine (mucomyst) (1 trial)

ambroxol (1 trial)

dolutegravir (tivicay) (1 trial)

lamivudine (epivir) (1 trial)

Drugs in Phase 1 Trials (1)

monepantel (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Motor Neuron Disease (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 6